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SUMMARY 
Background: The present mini review evaluates assessment and comorbidity of glaucoma and depression with the possibilities of 
treatment options.  
Subjects and methods: Web of science was searched for relevant articles using search terms "glaucoma", "depression", 
"glaucoma and depression", "quality of life and glaucoma". The additional relevant papers were added from the bibliography of 
selected papers. All types of articles were included, no time period was defined.  
Results: We have reviewed 11 studies regarding the comorbidities of glaucoma and depression. The number of participants in all 
studies ranged from 86 to 6760. Formats of scale in one study was clinician rated, others were self-reported scales. Two studies of 
the above mentioned studies explored specific types of glaucoma. In the three studies out of 11 there was no significant evidence of 
elevated depressive symptoms associated with glaucoma. In the six studies the prevalence of depression was significant among 
glaucoma patients. One study provided suboptimal assessments of depression in glaucoma patients. The other one showed the 
presence of glaucoma significantly associated with depression after adjustment for the demographic factor. Most of the studies used 
one scale, while two of them used two scales. The reviewed studies did not analyze the therapy options of included patients.  
Conclusion: The results presented in this review indicate that glaucoma is accompanied by depression in the majority of 
analyzed studies. The comorbidity of glaucoma and depression should be the subject of further research on both, self-reflecting and 
clinician-rated scales, taking into account subjective experience of patients and physicians. The therapy options should be taken into 
account in future researches focusing on the multidisciplinary approach including novel possibilities of treating both diseases 
respectively.  
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Introduction  
Glaucoma is a chronic, progressive, heterogeneous 
optic neuropathy which leads to visual field loss, 
disabilities and irreversible blindness if not diagnosed 
and treated at the right time. Glaucoma firstly affects 
peripheral vision and secondly central vision. Since it is 
silent, chronic disease with no clinical signs at the 
beginning of illness, it is often undiagnosed and under-
estimated (Eramudugolla et al. 2013). In many cases 
when diagnosed, glaucoma is already in advanced stage. 
Clinical trials confirmed the importance of intraocular 
pressure (IOP) in the development and progression of 
open-angle glaucoma, even if evidence suggests the 
existence of ocular and systemic factors, in addition to 
IOP, that can be responsible for this development and 
progression (Actis et al. 2016). These various risk 
factors may be organized into various categories (Ago-
rastos & Huber 2011, Nageeb & Kulkarni 2015): demo-
graphic (age, sex and race), lifestyle (smoking, alcohol), 
comorbidities (heart disease, peripheral hypertension, 
diabetes, obesity), ophthalmic risk factors (eye struc-
ture, central corneal thickness, corneal hysteresis, intra-
ocular pressure, myopia, cataract, vascular abnorma-
lities), family history, socioeconomic status and comp-
liance (Salowe et al. 2015). The point is that the main 
risk factor is ocular pressure (it is also the only one we 
can treat today), then we can discuss upon the others. In 
general, patients with visual impairment have higher 
prevalence of psychological disturbance – such as 
depression, anxiety or sleep disorders (Agorastos et al. 
2013, Eramudugolla et al. 2013, Rovner et al. 2014, 
Skalicky & Goldberg 2008). It was shown that the 
strongest connection between psychological distur-
bances and visual impairment disorder was depression 
(McCusker & Koola 2015, Actis et al. 2016, Spinelli et 
al. 1998). The level of depressive symptoms is higher in 
patients with multiple eye disease (Eramudugolla et al. 
2013, Pop-Jordanova et al. 2014). Dual sensory loss, 
such as visual and hearing impairment, increases even 
more the level of depressive symptoms (Kiely et al. 
2013). On the other hand, depression is one of the most 
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common psychological disturbances among patients that 
is comorbid with other chronic physical diseases in 
general (Jeong et al. 2016, Moussavi et al. 2007) with 
the most negative effect on the health score. Depression 
has also higher prevalence among older population 
(Skalicky & Goldberg 2008). The risk factors for the 
development of psychological disorders in glaucoma 
patients could be subjective and objective (Kong et al. 
2014). The age, sex, visual field loss (VFL) and the 
severity of glaucoma condition are some of the 
objective risk factors on which the patients have no 
influence (Kong et al. 2014). The subjective risk factors, 
such as regular and proper administration of topical 
antiglaucoma medication, education and proper under-
standing of character of the glaucoma disease or adop-
tion of healthy habits, could be influenced by patients. 
In the study among the Chinese patients, the compre-
hension of the character of glaucoma is an independent 
factor negatively related to psychological disturbance 
and positively related to the Quality of Life (QoL) 
among the glaucoma patients (Kong et al. 2014). The 
authors emphasize the value of education in establishing 
the healthy habits (the importance of compliance with 
the therapy) among the patients. The knowledge of 
glaucoma character with consequent understanding of 
the value of therapy compliance decreased psycho-
logical disturbance and contributed to the higher QoL. 
In the paper of Agorastos et al, visual field defects 
(VFD) were predictive factors of depression, anxiety 
and sleep disorder (Agorastos et al. 2013). The loss of 
everyday life abilities (driving the car, reading, moving 
indoors and outdoors, depending on the help of others) 
could be an important factor in developing depression in 
glaucoma patient.  
 
Methodology 
The literature search was performed by using 
PubMed and MEDLINE. The searched terms were 
“glaucoma”, “depression”, “glaucoma and depression”, 
“quality of life and glaucoma”. This mini review was 
limited to the articles published in English language. All 
types of relevant articles were included in the review, 
including the original research, reviews and other 
articles of interest. The additional relevant papers were 
added from the bibliography of selected paper. The time 
period was not defined. 
 
Pathophysiology of glaucoma and depression 
Ophthalmic risk factors for glaucoma onset and 
development are: first of all intraocular pressure (IOP), 
followed by eye structure (angle of the anterior 
chamber), central corneal thickness, myopia, cataract, 
and vascular abnormalities (Salowe 2015). The impor-
tant pathophysiological mechanism of glaucoma is 
redundant retinal oxidative stress (ROS) with the 
consequence on glaucomatous changes and neurode-
generation. The result is the loss of the intrinsically 
photosensitive retinal ganglion cells (ipRGC) with 
consequent disorder in melanopsin activity (Agorastos 
& Huber 2011), disruption of circadian rhythm and 
neuropathy of optic nerve (Agorastos et al. 2013, Ago-
rastos & Huber 2011, Ayaki et al. 2015). Consequently, 
the role of neurohormone melatonin (MLT) in the eye 
may be involved in the physiology and pathophysiology 
of retinal function (Agorastos & Huber 2011, Tosini et 
al. 2012). MLT has a potential use in the management 
of glaucoma (Agorastos & Huber 2011) as protector 
against oxidative stress in neurons, antioxidant in the 
retina, with direct effect on intraocular pressure (IOP) 
and interference on other glaucomatous risk factors 
(hypertension, diabetes).  
MLT has also an important role in the regulation of 
circadian rhythm by modulating electrical activities of 
neurons of suprachiasmatic nucleus. Changes in cir-
cadian system or chronodisruption can have an effect on 
sleep disturbance, seasonal affective disorders and de-
pressive disorders (Tosini 2012). Pathophysiology of 
depression is not unique and clearly defined. It was 
shown that serotonin (Dell'Osso 2016), norepinephrine, 
glutamate and dopamine have an important role in 
pathophysiology of depressive disorders (Niciu et al. 
2014). Recent researches indicate that MLT might have 
an important role in pathophysiology and possible 
therapy in many diseases, such as depression, diabetes, 
pain, neurodegenerative diseases, circadian and mood 
disorders, insomnia (Comai & Gobbi 2014), and vision 
disorder such as glaucoma (Agorastos & Huber 2011, 
Tosini 2012). MLT is synthesized from serotonin and 
acts through MT1 and MT2 receptors (Agorastos & 
Huber 2011, Comai 2014). In the study of Comai and 
Gobi MT2 receptors were involved in the patho-
physiology and pharmacology of depression (Comai & 
Gobbi 2014). In addition, MT1 and MT2 receptors were 
identified in mammalian retina (Tosini et al. 2012). 
Therefore, MLT might be connected with reducing of 
IOP (Tosini et al. 2012). Pathophysiological connection 
between depression and glaucoma might origin from the 
reduced absorption of light because of retinal disruption 
which leads to irregular melatonin synthesis as it was 
showed in various animal models (Tosini et al. 2012). 
The result is higher prevalence of depression, anxiety, 
and sleep disorder. 
There is no clear evidence of effectiveness of neuro-
protective agents on progression of OAG (Sena & 
Lindlsey 2017). Further clinical researche should plan to 
explore the benefits of neuroprotective agents on OAG 
and preservation of vision. 
 
Epidemiological data  
The epidemiological studies indicated an increase in 
the prevalence of glaucoma (Vost et al. 2015, Boyers et 
al. 2015, Ferrari et al. 2010, Tham et al. 2014, Wang et 
al. 2012). In 2013, 64,3 million people with glaucoma 
(aged between 40 and 80 years) were estimated. It is 
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calculated that the number of people with glaucoma will 
have increased up to 76,0 million by the year 2020 and 
up to 111,8 million by the year 2040 respectively (Tham 
et al. 2014). Since glaucoma affects mostly older 
population, whose prevalence has been significantly 
increased (Skalicky et al. 2015), it presents one of the 
global public health issues (Tsai et al. 2004, Chen et l 
2015). Global Burden of Disease Study 2013 had 
ranked the glaucoma prevalence with total percentage of 
1.29% in 1990, 1.41% in 2013, while the YLD (years 
lived with disabilities) ranked 3,58% in 1990, and 
4.02% in 2013. Glaucoma prevalence by severity was 
ranked in the same study in 2013; moderate 0.94%, 
severe 0.13% and blind 0.34% (Vost et al. 2015). The 
same study indicated significant percentage change in 
prevalence of glaucoma from 1990 to 2013 (50.2% vs 
74.7%) respectively, the significant changes are YLD 
from 1990 to 2013 (54.8% vs 70.9%) and in age-
standardized YLD from 1990 to 2013 (-9.7% vs -0.2%) 
(Vost et al. 2015). Glaucoma and macular degeneration 
global burden were overrepresented according to the 
Global burden of eye and vision disease as reflected in 
the Cochrane Database of Systematic Reviews (Boyers 
et al. 2015). This finding might suggest that certain 
diseases such as glaucoma attract much more attention 
of researchers than others, because of their importance 
in causing morbidity and disabilities.  
The results of Moussavis’ research, World Health 
Study (WHS) by World Health Organization (WHO), 
showed that one-year prevalence of depressive episode 
was 3.2 % in the 60 countries involved in research 
(Moussavi et al. 2007). In the case of comorbid 
depression (depression with chronic physical disease) 
the prevalence was significantly higher, between 9.3% 
and 23.0%. Depressive disorders were the second 
leading cause of YLD according to Global Burden of 
Disease Study 2010 (Ferrari et al. 2013) and 2013 
(Vost et al. 2015, Global Burden 2013, Kessler & 
Bromet 2013).  
According to the findings of several studies, (Wang 
et al. 2012, Mabuchi et al. 2012, Skalicky & Goldberg 
2008) which were undertaken worldwide, the preva-
lence of depression among glaucoma coincides. The 
prevalence of depression among glaucoma patients in 
the study of Wang et al. was 10.9% (Wang et al. 2012) 
as it was in the Japanese Clinical study (Mabuchi et al. 
2012). The range of the prevalence of depression in 
glaucoma patients was between 11.4% and 32.1% in the 
Australian clinical study performed by Skalicky et and 
Goldberg (Skalicky & Goldberg 2008).  
 
The quality of life of glaucoma  
patients with depression 
The concept of QoL in the last decades has become 
the focus of interest of many physicians, especially 
those who treat the chronic disease patients (Labiris et 
al. 2011). To comprehend the concept of QoL and its 
purpose in diagnosing and treatment of patients, the re-
searchers need to be aware of the parameters that 
comprise it: physical, functional, social, and psycho-
logical (Labiris et al. 2011). The comorbidity of 
depression and glaucoma interfere with all of them 
(Moussavi et al. 2007, Skalicky & Goldberg 2008). In 
the practice there are several instruments available 
(Severn et al. 2008, Labiris et al. 2011, Waisbourd et al. 
2015, Sprat et al. 2008, Valderes et al. 2004, Brown et 
al. 1998) for the assessment of the QoL of glaucoma 
patients that can be divided in three groups: Health 
related QoL, vision-specific QoL, and disease specific 
QoL – glaucoma specific instruments. Glaucoma 
specific tools have higher specificity for glaucoma. 
According to the literature (Labiris et al. 2011, Severn 
et al. 2008, Spratt et al. 2008), there are no ideal or 
generally used Qol instruments for glaucoma. But 
regardless of that, most of the conducted studies showed 
that glaucoma patients have lower Qol scores and less 
functional status (Tsai et al. 2003, van Gestel et al. 
2010, Wilson et al. 1998). It was shown that the visual 
impairment limits the QoL of patients (Skalicky et al. 
2015, Labiris et al. 2011). The depression comorbid 
with chronic conditions such as glaucoma worsen the 
health status of patients (Moussavi et al. 2007) and have 
negative implication on the QoL. It was shown that the 
age related eye diseases like glaucoma are associated 
with poorer health related quality of life (HRQoL) (Li et 
al. 2011, Tsai et al. 2004) by worsening poor general 
health, physical and mental unhealthy days such as 
limitation of daily activities. Contrary, HRQoL did not 
deteriorate in glaucoma patients in the study of Esteban 
et al. (Esteban et al. 2008). Deterioration of glaucoma 
with VFL is associated with the loss in glaucoma-
specific QoL and general health QoL (van Gestel et al. 
2010). As the last study indicated, two types of QoL 
instruments (general health and glaucoma-specific 
instruments) might be used to assess the proper Qol in 
glaucoma patients.  
 
Assessment of depression in glaucoma patients  
The analyzed literature in this paper provides an 
overview of instruments used for assessment of de-
pression in glaucoma patients (Gothwal et al. 2014, 
Cumurcu et al. 2006, Skalicky & Goldberg 2008, 
Wang et al. 2012, Ayaki et al. 2015, Kiely et al. 2013, 
Eramudugolla et al. 2013, Wilson et al. 2002, 
Agorastos et al. 2013, Kong et al. 2014). The scree-
ning of the depression like disorder, diagnose of the 
disorder, assessment of severity of disorder, and the 
measurement of changes in severity of disorders 
represent the main purpose of assessment of the scales 
for depression (Furukawa 2010). The psychiatric 
assessments can be organized in two formats: clini-
cian-rated and self-report (Furukawa 2010).  
Hamilton Depression Rating Scale (HDRS) is clini-
cian-rated scale with 21 items for assessing the severity 
and measuring the changes of depression (Furukawa 
2010, Cumurcu et al. 2014). 
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Table 1. The comparison between reviewed studies based on the assessment of depression, format of rating scales for 
depression, format of glaucoma assessment and total number of participants 
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Montgomeri-Asberg Depression Rating Scale 
(MADRS) is clinician-rated instrument created with the 
purpose of measuring the severity and changes of 
depression (Furukawa 2010, Cumurcu et al. 2006).  
Center for Epidemiological Studies Depression Scale 
(CES-D) is 20 item, self-repot instrument which respon-
ses are based on depression symptoms experienced one 
week before the testing. It is used for epidemiological 
studies of depression in population (Wilson et al. 2002, 
Kiely et al. 2013).  
Composite International Diagnostic Interview-Short 
Form (CIDI-SF) scale was originally constructed by 
WHO for assessment of mental disorder. CIDI-SF 
assesses 8 of 9 symptoms for diagnosing the depressive 
episode (criteria of Diagnostic and Statistical Manual of 
Mental Disorder, 4th Edition of American Psychiatric 
Association) (Gigantesco & Morosini 2008, Wilson et 
al. 2002). 
Hospital Anxiety and Depression Scale (HADS) is 
self-report, created to detect anxiety and depression. It is 
broadly used in hospital-based surveys, (Kong et al. 
2015, Ayaki et al.). It contains two subscales (depres-
sion and anxiety), both with 7 items. The answers are 
based on the relative frequency of symptoms over the 
past week. 
Beck’s Depression Inventory-Second Edition (BDI-
II) is 21 item self-report and possible self-scored scale 
for screening of severity and measuring of changes in 
depression (Furukawa 2010, Agorastos et al. 2013, Pop-
Jordanova et al. 2014).  
Goldberg Anxiety and Depression Scales (GADS) is 
self-completed, 18 item questionnaire designed for 
measurements of the anxiety and depression (9 anxiety 
and 9 depression items) (Koloski et al. 2008g, Eramu-
dugolla et al. 2013). 
Patient-Health Questionnaire (PHQ)-9 is 9 item, 
self-report version of Primary Care Evaluation of 
Mental Disorders (PRIME-MD) developed in 1999 
(Furukawa 2010, Wang et al. 2012, Gotwall et al. 2014). 
The purpose of PHQ-9 is self-reported screening of 
depression, measuring of severity and measuring of 
changes in depression. The responds are ranked based 
on the frequency of depressive symptoms over the 
previous two weeks. In the analyses of validity for 
screening PHQ-9 showed substantial heterogeneity 
which was not explained (Furukawa 2010). PHQ-9 
provided suboptimal assessment of depression in 
glaucoma patients in India, in Study of Gothwal et al. 
(Gotwall et al. 2014).  
Geriatric Depression Scale-15 (GDS-15) is self-
report instrument with 15 items used to assess de-
pression in elderly population (Skalicky & Goldberg 
2008). 
Self-rating Depression Scale (SDS) is 20 item, self-
reported scale, used to asses affective, psychological 
and somatic symptoms associated with depression. The 
responses are ranked according to the frequency of 
symptoms in the past several days (Kong et al. 2015). 
Depression and glaucoma – studies  
On the basis of the above mentioned scales, 11 
studies were extracted in this review. The prevalence of 
depression in patients with visual impairment is the 
issue of research in many studies (Ayaki et al. 2015, 
Eramudugolla et al. 2013, Wang et al. 2012, Skalicky & 
Goldberg 2008). For example, in four of the extracted 
studies the prevalence of depression in glaucoma pa-
tients was significantly higher (Ayaki et al. 2015, Pop-
Jordanova et al. 2014, Agorastos et al. 2013, Skalicky & 
Goldberg 2008). The HADS score for depression was 
the highest in glaucoma patients in comparison to other 
patients with visual impairment in the study of Ayaki et 
al. (Ayaki et al. 2015). This study was primary designed 
for the assessment of prevalence of sleep and mood 
disorders in the eye clinic patients. The total number of 
participants was 730, only 109 of them were glaucoma 
patients (e.g. Table 1). The severity of glaucoma and 
older age of the patients, in the study of Skalicky and 
Goldberg, contributed to higher prevalence of depres-
sion in glaucoma patients (Skalicky & Goldberg 2008). 
The purpose of this study was also to determinate the 
association of depression and the QoL in glaucoma 
patients. Glaucoma specific instrument Glaucoma Qua-
lity of life-15 (GQL-15) was used for the QoL assess-
ment. The results showed decreased quality of life with 
worsening severity of glaucoma. The total number and 
share of glaucoma patients are shown in the table 1. The 
increasing trend of depression in this study might be due 
to decrease of central and peripheral vision with 
consequent reduction of subjective and objective visual 
function. In the study of Agorastos et al, the VFL in 
glaucoma was the principal predictive factor of depres-
sion (Agorastos et al. 2013) and other psychological 
disturbances. One of the main messages of this study is 
the necessity of screening for psychological disturbance 
and psychochronobiological treatment of glaucoma pa-
tients. The importance of regular screening for depres-
sion in glaucoma patients supports also the findings of 
the study of Pop-Jordanova et al, which show that 
depression was often unrecognized and untreated pro-
blem (Pop-Jordanova et al. 2014). The prevalence of 
depression was often higher in the patients with severe 
ophthalmological disturbances (glaucoma, age-related 
macular degeneration, proliferative diabetic retinopathy 
and cataract) in the study of Pop-Jordanova (Pop-
Jordanova et al. 2014) which is consistent with the study 
of Skalicky and Goldberg (Skalicky & Goldberg 2008). 
In addition the level of depression was found higher in 
the elderly population which is in coincidence with both 
the above mentioned studies (Skalicky & Goldberg 
2008, Pop-Jordanova et al. 2014).  
The two papers from this review reported comor-
bidity of specific type of glaucoma and depression 
(Cumurcu et al. 2006, Kong et al. 2015). The study of 
Cumurcu et al, discussed the association of pseudoexfo-
liative glaucoma (PXG) and depression (Cumurcu et al. 
2006). The PXG patients were more depressed then 
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patients with primary open angle glaucoma (POAG) and 
control group. The same study showed no significant 
differences in the anxiety scale comparing PXG or 
POAG group respectively, and the control groups. The 
higher level of depression was associated with the 
patients with primary angle closer glaucoma (PACG) in 
contrast to patients with POAG and control group in the 
study of Kong et al. (Kong et al. 2015). Both studies 
compared POAG with other types of glaucoma and both 
studies showed that patients with POAG were less 
depressed. However, on the basis of these two studies, it 
could not be possible to conclude that POAG patients are 
less depressed than patients who suffer from other types 
of glaucoma. The existence of association of certain type 
of glaucoma and depression (Cumurcu et al. 2006, Kong 
et al. 2015) should be evaluated in further studies. 
In the three studies (Eramudugolla et al. 2013, Wil-
son et al. 2002, Kiely et al. 2013), there were no signifi-
cant correlation between depression and glaucoma. 
Eramudugolla et al. associated such findings with self-
reported knowledge of glaucoma that might have 
compromised the result because glaucoma is often 
underdiagnosed in population (Eramudugolla et al. 
2013), which is consistent with the previous study of 
Pop-Jordanova (Pop-Jordanova et al. 2014). The same 
indicates the study of Kiely et al, e.g. there is no 
increase of depression in patients with only visual field 
loss (corrected distance visual acuity>0,3 longMar in 
the better eye, self-reported blindness and glaucoma) 
(Kiely et al. 2013). The glaucoma patients did not report 
higher depression than patients without glaucoma in the 
study of Wilson et al. (2002). 
Finally, the last two studies from this review, which 
used PGQ-9 scale, did not have congruent results 
(Wang et al. 2012, Gothwal et al. 2014). PHQ-9 instru-
ment in the study of Gothwal et al. with 198 patients did 
not provide optimal assessment of depression in glau-
coma patients (Gothwal et al. 2014). In the study of 
Wang et al. (2012), where the PHQ-9 scale was also 
used, the presence of correlation between depression 
and glaucoma had no significance without the adjust-
ment. The authors used two models of adjustments: 
adjustments for demographic factors and for the self-
report of the general health condition. The model in 
which glaucoma and depression were adjusted for the 
demographic factors, the association of glaucoma and 
depression, was significant. The model with adjustment 
for the general health condition found no significant 
correlation with glaucoma and depression. We can 
calculate that PHQ-9 is not the instrument of choice for 
the assessment of depression in glaucoma patients. On 
the other hand, Furukawa reported (Furukawa 2010) 
PHQ-9 as an instrument with excellent psychometric 
properties but with substantial heterogeneity in scree-
ning validity, which could not be explained. 
There are no unique results of the studies regarding 
the association of depression with glaucoma (McCusker 
& Koola 2015, Kiely et al. 2013, Wilson et al. 2002, 
Tosini et al. 2012, Eramudugola et al. 2013, Skalicky & 
Goldberg 2008) using different measurement instru-
ments (e.g. Table 1). Table 1 recapitulates the compa-
rison between reviewed studies based on the assessment 
of depression, format of rating scales for depression, 
format of glaucoma assessment and the total number of 
the participants with the share of glaucoma patients (e.g. 
Table 1). Only one study used clinician-rated scales 
(HDRS and MADRS) for the assessment of depression 
in glaucoma patients (Cumurcu et al. 2006). Most of the 
studies used objective visual tests for glaucoma 
assessment. Only in two studies glaucoma was assessed 
by self-report method (Ermudugolla et al. 2013, Wang 
et al. 2012). In the first study, there was no evidence for 
elevated rates of depression in glaucoma (Ermudugolla 
et al. 2013). The total number of participants and the 
number of glaucoma patients varied widely among 
reviewed studies (e.g. Table 1). The total number of 
participants ranged from 6760 to 86. The range of 
glaucoma patients varied from 10 to 453. In one study 
the number of glaucoma patients was unknown (Kiely et 
al. 2013). Some of the studies were performed only with 
the glaucoma patients (Gothwal et al. 2014, Agorastos 
et al. 2013), while others had combination of patients 
with visual impairment, control group. One of the issues 
which could have influenced the results was the range 
of glaucoma patients in the study. 
 
Management of patients who suffer  
from glaucoma and depression 
The aging of population, the increase in various 
comorbidities, the various available medications and the 
organization of health care pose a great challenge for 
clinicians in the management of chronic patients today.  
By focusing only on the treatment of glaucoma, 
comorbidities are often neglected. Depression as a 
comorbid condition deteriorates the health of the 
patients more than depression alone or more than other 
chronic conditions, alone or in combination of different 
chronic diseases without depression (Moussavi et al. 
2007). Chronic conditions such as glaucoma may be 
associated with depression due to the age of patients 
(Jeong et al. 2006, Kong et al. 2014), prolonged daily 
use of antiglaucoma medications, limitation of daily 
activities, limitation of family and working roles 
(Guedes et al. 2012). 
The antiglaucoma medication is mostly topical appli-
cation. The possibilities of systematic adverse effects are 
uncommon but they are still possible (Jeong et al. 2016). 
For example, the caution with regard to use of ocular 
beta-blockers was recommended in the case of depres-
sion, asthma and heart disease. However, recent studies 
did not find any correlation between beta-blocker use 
and depression (Wilson et al. 2002). The recent studies 
have also suggested that phenylephrine eye drops had no 
clinically relevant effects on the heart rate or blood pres-
sure as was previously suggested (Stavert et al. 2015).  
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The topical administration of antiglaucoma medica-
tions, on the other hand, has very common topical side 
effects (Guedes et al. 2012, Servat & Bernardino 2011, 
Park et al. 2013) such as eyelid dermatitis, lacrimal 
system scarring, ocular discomfort upon instillation, 
conjunctival inflammation and conjunctival epithelium 
changes, corneal surface and endothelial impairment, 
blurred vision, a stinging sensation etc. The patients 
diagnosed with glaucoma during the period when the 
symptoms of visual field and visual function loss had 
not still been developed, could only experience the 
disturbing side effects of antiglaucoma therapy. As a 
result, some of the early diagnosed glaucoma patients 
might give up on therapy. The initial education of 
patients regarding the possibilities of side effects of 
the antiglaucoma therapy and the severe consequences 
of nonadherence to it is very important (Park et al. 
2013).  
The price of medications, the difficulties with 
administration and dosing schedule might contribute to 
poor compliance, worsening IOP, and consequently 
depression. The patient is in vicious circle.  
The different situation with the same result appears 
in patients with good compliance, sometimes multiple 
ophthalmological therapy (surgery and multiple 
medications), regular follow-ups, with the result of 
advanced glaucoma and VFL with the respond of 
depression (Gothwal et al. 2014).  
Administration of psychiatric medication can cause 
glaucoma (Jeong et al. 2016). Tricyclic antidepressants 
can lead to closed-angle glaucoma because of anticho-
linergic activity. Because of epinephrine receptor blo-
ckade, some of the antipsychotic drugs can also cause 
closed-angle glaucoma. Selective serotonin inhibitors 
and benzodiazepines can generate in closed-angle 
glaucoma. Long-term use of selective serotonin reup-
take inhibitors (SSRI), which are the most prescribed 
type of medication for depression, does not significantly 
influence the risk of POAG and PACG (Chen et al. 
2015). One of the future possibilities in the management 
of comorbidity of glaucoma and depression is MLT, as 
it was described in the papers of Agorastos and Huber 
(Agorastos & Huber 2010), and Tosini et al. (Tosini 
2012).  
The character of depression with the hopelessness 
and pessimism may cause poor compliance and with-
drawal of the therapy (Jeong et al. 2016). 
Besides the standard therapy of glaucoma, topical 
antiglaucoma medications and surgery, novel appro-
aches such as melatonin (Agorastos & Huber 2011, 
Tosini et al. 2012), endocannabinoid system (Cairns et 
al. 2016), and bone-marrow mesenchymal stem cell 
(Roubeix et al. 2015) should be explored.  
Cognitive deficits are often comorbid with depres-
sion (Joeng et al. 2016). Due to cognitive deficit the 
patients are not able to comprehend the character of 
glaucoma and the necessity of adherence to the therapy 
which leads to worsening of glaucoma and blindness. 
The management of the patients with comorbidity of 
glaucoma and depression should be organized on the 
basis of a multidisciplinary approach (Jeong et al. 
2016). An ophthalmologist has to recognize and take 
into account a state of depression when the treatment 
plan is made (Moussavi et al. 2007). 
The organization of health care in the case of sub-
specialist glaucoma ambulance is an important factor in 
the management of glaucoma patients (the time for the 
review; education about the characteristics of glaucoma, 
possibilities and side effects of treatment; the real role 
of glaucomatologyst, the role of a subspecialty nurse). 
The next step should be the involvement of a multi-
disciplinary team consisting of psychologists, psychia-
trists and rehabilitation therapists (Rovner et al. 2014). 
 
Conclusion 
The results presented in this review indicated that 
glaucoma is accompanied by depression in the majority 
of analyzed studies. The rating scales used in assessing 
depression in studies analyzed in this review had different 
purposes and different formats. The questionable is con-
nection of formats of instruments used in the studies 
(self-reporting or clinician-reporting) and assessments or 
no assessment of depression. Besides the issues of diffe-
rent instruments, formats of assessments and the number 
of participants in the studies, subjective experience of pa-
tients and physicians should be taken into account when 
assessing the depression in glaucoma patients (Wang et 
al. 2012). The reviewed studies did not analyze therapy 
options of glaucoma patients with depression. The treat-
ment of comorbidity of glaucoma and depression should 
not depend only on ophthalmologist or psychiatrist, the 
assessment of treatment should be multidisciplinary. New 
approaches, such as MLT administration, should be taken 
into account in the management of glaucoma patients 
with depression. The management of glaucoma and 
depression should be comprehended as a public-health 
issue because of epidemiological data regarding the rising 
prevalence of both chronic diseases worldwide.  
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